Aiming at the brain’s nicotine receptors
Drug | Company | Indication | Stage |
---|---|---|---|
Chantix/Champix (varenicline) | Pfizer | Smoking cessation | Approved |
TC-5214 | AstraZeneca/Targacept | Major depressive disorder | Phase III |
AZD3480 | AstraZeneca/Targacept | Alzheimer’s disease | Phase IIb |
Adult attention-deficit hyperactivity disorder (ADHD) | Phase II | ||
CP-601927 | Pfizer | Major depressive disorder | Phase II |
AZD1446 | AstraZeneca/Targacept | Alzheimer’s disease | Phase I |
Adult ADHD | Phase II |
Social Media Box - AML